[ET Net News Agency, 1 June 2020] BOCOM Research lifted its target price for Sino
Biopharmaceutical (SBP)(01177) to HK$14.08 from HK$12.41 and maintained its "buy" rating.
The research house said SBP's 1Q adjusted attributable net profit of RMB834m missed
BOCOM's estimate by 4.3%. Growth was mainly dragged by hospital shutdown during the
pandemic, while rising R&D cost further weighed on profit.
Oncology portfolio, however, showed continued strong growth, which will be sustained by
Anlotinib's indication expansion, PD-1's launch in 2021, and Abiraterone & Gefitinib that
won the bid in PTQ (procurement with target quantity), BOCOM noted.
BOCOM revised its 2020-22 attributable net income by -6.7%/1.7%/6.9%. (KL)